Semaglutide CAS 910463-68-2 Raw Powder

Related Attributes

Product details

Semaglutide Powder Usage and Synthesis:

Semaglutide is a medication used to treat type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists, which work by increasing the production of insulin and reducing the amount of glucose produced by the liver. Semaglutide is administered once a week by injection and has been shown to effectively lower blood sugar levels and reduce the risk of cardiovascular events in people with type 2 diabetes. It is also being studied for its potential use in weight management.

Common side effects of semaglutide include nausea, vomiting, and diarrhea.Semaglutide Powder works better for type 2 diabetes. Semaglutide Raw Powder is a new generation of GLP-1 (glucagon-like peptide-1) analogues. Semaglutide CAS 910463-68-2 is a long-acting formulation based on the basic structure of Liraglutide, which is highly effective in the treatment of type 2 diabetes. Pharmaceutical Factory -Henrikang is Semaglutide Supplier.

Applications of Clobetasol Semaglutide Powder :

Semeglutide is a novel GLP-1 analogue injected subcutaneously once a week. Sommarutide is a long-acting GLP-1 analogue developed by Novo Nordisk with 1 /w subcutaneous injection. Compared with Lilarutide, Sommarutide has longer fat chain and increased hydrophobicity, but Sommarutide is modified with short chain PEG, which greatly enhances hydrophilicity.

PEG modification can not only bind with albumin closely, cover the hydrolysis site of DPP-4 enzyme, but also reduce renal excretion, prolong biological half-life, and achieve the effect of long cycle. Novo Nordisk's Sommarutide hits DPP-4's Sitagliptin and GLP-1's progenitor Exenatide (should be designed to compete head-to-head with lilly's trulicity, Bully has long been on the market). High dose soma decreased A1C1.6% and decreased body weight by up to 6kg.

Pharmacological Effect of Semaglutide Powder:

(1) 3183 patients with type 2 diabetes were enrolled in a randomized placebo-controlled clinical trial. Patients were given sommarutide or placebo daily for a median of 15.9 months.

(2) The incidence of major adverse cardiovascular events was 3.8% in the Sommarutide group and 4.8% in the placebo group, indicating that Sommarutide was significantly non-adverse compared with placebo.

(3) The main adverse cardiovascular events included: death from cardiovascular disease, non-fatal myocardial infarction and non-fatal stroke;

(4) Sommarutide significantly reduced cardiovascular disease mortality and all-cause mortality, and did not significantly increase the risk of nonfatal myocardial infarction and nonfatal stroke.

Method of Preparing Semaglutide Powder:

Sommarutide was prepared by solid-liquid synthesis method. Linear peptide Aib8, Arg34GLP-1(7-37) and aliphatic acylating agent were prepared by solid-phase synthesis. Under alkaline conditions, the synthetic aliphatic acylating agent was used to modify the linear peptide Lys26 to obtain sommaruteptide. The biological activity of the self-made samples was determined by time-resolved fluorescence resonance energy transfer immunoassay.

Why choose us?

HRK Factory

About Shipping